Product News

Forest Laboratories, Inc. (NYSE: FRX) reported that today the U.S. District Court for the District of Delaware has rescheduled opening arguments from May 9, 2005 to December 5, 2005 for the trial related to patent litigation regarding the SSRI antidepressant Lexapro(R). Forest Laboratories, Inc., Forest Laboratories Ireland Ltd. and H. Lundbeck A/S are plaintiffs with co-defendants being Ivax Pharmaceuticals, Inc / Cipla Ltd. and Alphapharm Pty more...

Forest Laboratories, Inc. (NYSE: FRX) announced today that the U.S. Food and Drug Administration (FDA), following its initial review of a supplemental New Drug Application for Lexapro (R) (excitalopram oxalate), an SSRI antidepressant, for the treatment of Social Anxiety Disorder (SAD), has determined the application not approvable.

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today reported that the U.S. Food and Drug Administration (FDA) has issued a second non-approvable letter for the indication of Panic Disorder for Lexapro(R) (escitalopram oxalate), an SSRI antidepressant.

Forest Laboratories, Inc. (NYSE: FRX) announced today that Campral(R) (acamprosate calcium) Delayed- Release Tablets are now available to physicians, patients and pharmacies nationwide. Campral was approved by the U.S. Food and Drug Administration (FDA) on July 29, 2004 for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with Campral should be part of a more...

Glenmark Pharmaceuticals S.A (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL), and Forest Laboratories, Inc. (NYSE: FRX) have entered into a collaboration agreement for Glenmark's PDE4 inhibitor GRC 3886.

Forest Laboratories, Inc. (NYSE: FRX) announced today that it has submitted a complete response to deficiencies raised by the FDA Division of Neuropharmacological Drug Products in its review of the Panic Disorder supplemental NDA submitted for Lexapro in April, 2003. Lexapro is approved for use in Major Depressive Disorder and Generalized Anxiety Disorder. An additional Supplemental NDA is under FDA review for Social Anxiety Disorder.

Forest Laboratories, Inc. (NYSE: FRX) announced today the results of a recently completed placebo- controlled study of Lexapro(R) (escitalopram oxalate) in children and adolescents. Patients receiving Lexapro did not demonstrate statistically significant separation from placebo in the primary efficacy measure, the mean change from baseline in the Children's Depression Rating Scale-Revised (CDRS-R) score.

Forest Laboratories, Inc. (NYSE: FRX) today announced the results of a clinical study, which found that Lexapro(TM) (escitalopram oxalate) is a beneficial and well-tolerated treatment for depressed patients who failed to respond to initial antidepressant therapy with any one of four other selective serotonin reuptake inhibitors (SSRIs). In addition, 60 percent of patients who were switched to Lexapro responded and more than 40 percent achieved more...

Forest Laboratories, Inc. (NYSE: FRX) announced today the results of a randomized, placebo- controlled, PET (positron emission tomography) imaging pilot study designed to measure the effect Namenda(TM) (memantine HCl) has on functional brain activity in patients with mild to moderate Alzheimer's disease. The results in this pilot study suggest that, compared to placebo-treated patients, treatment with Namenda may positively affect cerebral more...

Forest Laboratories, Inc. (NYSE: FRX) announced today the results of a six-month study, which found that Lexapro(R) (escitalopram oxalate) is as effective as Paxil(R) (paroxetine hydrochloride) in patients with generalized anxiety disorder (GAD). When compared to Lexapro-treated patients, three times as many Paxil-treated patients withdrew from the study due to adverse events, and more than twice as many Paxil-treated patients experienced weight more...

Forest Laboratories, Inc. (NYSE: FRX) announced today the presentation of new data on behavioral outcomes from the first clinical trial evaluating the treatment of patients with moderate to severe Alzheimer's disease with a combination of two available Alzheimer's drugs: Namenda(TM) (memantine HCl) and donepezil.